Gene Therapy for Post-Operative Atrial Fibrillation

Atrial Fibrillation Clinical Trial

— AFGT01  

Official title:

AdKCNH2-G628S Gene Therapy for Post-Operative Atrial Fibrillation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05223725
• Other study ID #: WIRB1333791
• Secondary ID: 4R33HL158541
• Status: Recruiting
• Phase: Phase 1
• Start date: October 1, 2023
• Est. completion date: August 2026

Study information

• Verified date: October 2023
• Source: University of Massachusetts, Worcester
• Contact: Kevin Donahue, MD
• Phone: 508-421-1538
• Email: Kevin.Donahue[@]umassmed.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial will have 2 components: a brief dose-ranging study and a randomized comparison of 2 doses of AdKCNH2-G628S with control cardiac surgery patients. The study will assess safety of the intervention in a population at increased risk for post-operative atrial fibrillation.

Description:

Post-operative AF (POAF) is a specific form of AF occurring in the days after cardiothoracic surgery. A unique element of POAF is the limited duration of risk, which peaks 3 days and dissipates 10 days after surgery. We propose gene therapy for POAF. Our hypothesis is that counteracting AF-related electrical remodeling will disrupt the reentrant electrical circuits integral to maintaining AF. We have extensive preclinical data showing safety and efficacy of adenoviral gene transfer using the gene mutation KNCH2-G628S. When delivered to the atria using adenoviruses and a novel gene painting technique, KCNH2-G628S effectively and specifically prolongs atrial action potential and prevents development of AF for the 10-14-day duration of post-operative AF risk. This clinical trial will have 2 components: a brief dose-ranging study and a randomized comparison of 2 doses of AdKCNH2-G628S with control cardiac surgery patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 78
• Est. completion date: August 2026
• Est. primary completion date: August 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion:

• Elective valve surgery (alone or with coronary artery bypass grafting surgery) and one of the risk factors listed below, or elective coronary artery bypass grafting surgery with two of the risk factors listed below.
• Risk factors:
• age greater than 70,
• increased left atrial size (> 4 cm left atrial diameter or LA volume index > 35 on echocardiogram).
• obesity (body mass index > 30)
• history of:
• paroxysmal AF
• hypertension
• chronic pulmonary disease
• diabetes mellitus
• clinical heart failure
• rheumatic heart disease

Exclusion:

• persistent or permanent AF
• QTc > 475 on pre-op ECG or any time in last year (unless due to QT prolonging drug that was stopped > 5 half-lives before surgery with verification of QT normalization after discontinuing drug)
• QTc prolonging drug use (unless stopped > 5 half-lives prior to surgery)
• Any antiarrhythmic drug use in last year (inclusive of Vaughan Williams class I and III drugs, not including ß-blocker or calcium channel blocker drugs)
• Any history of inherited arrhythmia syndrome
• Any prior or current sustained ventricular arrhythmias
• Any prior or current clinically significant bradyarrhythmias unless already treated with pacemaker and ventricular pacing <20% (to reliable measure QT interval during the study)
• Any prior gene therapy
• Left ventricular ejection fraction (LVEF) < 35%
• Prior open chest surgery
• History of or current malignancy, unless documented to be cured
• History of or current chemotherapy, radiotherapy, or other immunosuppressive therapy within the past 30 days. Corticosteroid treatment may be permitted at the discretion of the Primary Investigator
• History of infection with human immunodeficiency virus (HIV), hepatitis A, B, or C, or tuberculosis
• Immunizations of any kind in the month prior to surgery
• Underlying defect in immune function or history of multiple or severe life-threatening infections
• Significant liver disease (active hepatitis, AST or ALT greater than twice the upper limit of normal, prior or current liver failure with Pugh-Child category A-C disease)
• Significant renal disease (GFR less than 30)
• Current pregnancy
• Childbearing potential unless participant agrees to prevent pregnancy prior to and for at least 3 months after virus delivery 10
• Any condition that limits life to < 12 months other than the condition to be treated with the planned surgery
• Participation in any other clinical trial within 30 days of surgery
• Incarcerated persons
• Individuals under the age of 18 years
• Unwillingness to undergo the study interventions and follow-up as outlined in the schedule of events
• Ongoing medical or other condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study
• Lack of capacity to provide participant's own informed consent.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Post-operative Atrial Fibrillation

Intervention

Biological:
• AdKCNH2-G628S
adenovirus containing the transgene KCNH2-G628S

Locations

Country	Name	City	State
United States	UMass Memorial Hospital	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Kevin Donahue	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010 Jun 1;121(21):2263-70. doi: 10.1161/CIRCULATIONAHA.109.911156. Epub 2010 May 17. — View Citation

Kikuchi K, McDonald AD, Sasano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation. 2005 Jan 25;111(3):264-70. doi: 10.1161/01.CIR.0000153338.47507.83. Epub 2005 Jan 10. — View Citation

Liu Z, Hutt JA, Rajeshkumar B, Azuma Y, Duan KL, Donahue JK. Preclinical efficacy and safety of KCNH2-G628S gene therapy for postoperative atrial fibrillation. J Thorac Cardiovasc Surg. 2017 Nov;154(5):1644-1651.e8. doi: 10.1016/j.jtcvs.2017.05.052. Epub 2017 May 23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	proportion of patients having a post-operative complication relative to controls	proportion of patients having a post-operative complication relative to controls	3 months
Secondary	proportion of patients having post-operative atrial fibrillation	proportion of patients having post-operative atrial fibrillation	1 month